Table 8.1 Information about the...

Table 8.1

Information about the different data available to work with in the distinct stages of the project. The table shows five main groups of information: gender and ageranges that help in handily dividing the population into ten different sub-populations, creating one group for each Cartesian combination of gender and age-range; the 19 diseases used to establish the different comorbidity groups with a hierarchical and statistical outlook; the clinical features, another group of ordinal variables used as explanatory variables for the patient models in each comorbidity group; and the two objective variables (risks) of the modularizations.

	Gender (number of individuals)
Man	(1,689,036)
Woman	(1,828,192)

	Age-ranges (number of individuals)
25+	(433,394) [25–39]
40+	(1,125,338) [40–54]
55+	(896,373) [55–69]
70+	(640,417) [70–84]
85+	(421,706) [85–8]

	List of diseases selected (number of individuals)
1. Anemia (632,229)	11. Dislipidemia (1,330,191)
2. Anxiety (1,119,416)	12. Hypertension (1,134,860)
3. Asthma (155,172)	13. Heart Failure (135,323)
4. Atrial Fibrillation (180,232)	14. Hypothyroidism (256,199)
5. Cardiomiopathy (29,673)	15. NAFLD (65,189)
6. Cirrhosis (112,602)	16. Osteoarthritis (270,860)
7. COPD (332,735)	17. Stroke (182,743)
8. Chronic Kidney Disease (144,444)	18. Vascular Dementia (31,404)
9. Dementia (187,546)	19. Venous Thromboembolism (49,752)
10. Diabetes (489,547)

	List of diseases selected (number of individuals)
1. Anemia (632,229)	11. Dislipidemia (1,330,191)
2. Anxiety (1,119,416)	12. Hypertension (1,134,860)
3. Asthma (155,172)	13. Heart Failure (135,323)
4. Atrial Fibrillation (180,232)	14. Hypothyroidism (256,199)
5. Cardiomiopathy (29,673)	15. NAFLD (65,189)
6. Cirrhosis (112,602)	16. Osteoarthritis (270,860)
7. COPD (332,735)	17. Stroke (182,743)
8. Chronic Kidney Disease (144,444)	18. Vascular Dementia (31,404)
9. Dementia (187,546)	19. Venous Thromboembolism (49,752)
10. Diabetes (489,547)

	Clinical features levels (number of records)
1. Smoker:	0: No Smoker, 1: Smoker
2. TAS: (mmHg) (2,140,114)	0: < 100, 1: 100 – 139, 2: > 139
3. TAD: (mmHg) (2,143,090)	0: < 80, 1: 80 – 89, 2: > 89
4. Glucose: (mg/dL) (2,404,397)	0: 0 – 125, 1: > 125
5. HbA1c: (%) (1,031,080)	0: 0 – 7, 1: > 7
6. Creatinine: (mg/dL) (2,401,173)	0: 0 – 1.5, 1: > 1.5
7. LDL Cholesterol: (mg/dL) (2,221,718)	0: 0 – 100, 1: > 100
8. HDL Cholesterol: (mg/dL) (2,235,509)	0: 0 – 44, 1: > 44

	Clinical features levels (number of records)
1. Smoker:	0: No Smoker, 1: Smoker
2. TAS: (mmHg) (2,140,114)	0: < 100, 1: 100 – 139, 2: > 139
3. TAD: (mmHg) (2,143,090)	0: < 80, 1: 80 – 89, 2: > 89
4. Glucose: (mg/dL) (2,404,397)	0: 0 – 125, 1: > 125
5. HbA1c: (%) (1,031,080)	0: 0 – 7, 1: > 7
6. Creatinine: (mg/dL) (2,401,173)	0: 0 – 1.5, 1: > 1.5
7. LDL Cholesterol: (mg/dL) (2,221,718)	0: 0 – 100, 1: > 100
8. HDL Cholesterol: (mg/dL) (2,235,509)	0: 0 – 44, 1: > 44

	Risk (Hospitalization and mortality) of interest (number of records)
1. Exitus:	0: non-dead, 1: dead. (355,021 subjects)
2. Hospitalization:	0: the cause of hospitalization is none of the diseases of the comorbidity group, 1: the cause of hospitalization is one or more of the diseases that forms the comorbidity group. (3,966,827 admissions) (1,646,059 subjects)

	Risk (Hospitalization and mortality) of interest (number of records)
1. Exitus:	0: non-dead, 1: dead. (355,021 subjects)
2. Hospitalization:	0: the cause of hospitalization is none of the diseases of the comorbidity group, 1: the cause of hospitalization is one or more of the diseases that forms the comorbidity group. (3,966,827 admissions) (1,646,059 subjects)

[ViewLarge]

Sharing Unavailable